ONO Pharmaceutical Reports Results of Opdivo (Nivolumab) in P-III ATTRACTION-3 Study in Patients with Unresectable or Recurrent Esophageal Cancer

•  The P-III ATTRACTION-3 study involves assessing of Opdivo (involumab, IV) vs CT (docetaxel/paclitaxel)
  in patients with unresectable advanced or recurrent esophageal cancer or intolerant to fluoropyrimidine + PT-based drug
• The study demonstrated in meeting 1EPs with superiority in overall survival of Opdivo vs CT
• Opdivo(Nivolumab) is a PD-1 immune checkpoint inhibitor targeted against cancer cells. In 2011, BMS and ONO to develop and commercialize Opdivo where ONO retains rights in Japan, South Korea and Taiwan

Click here to read full press release/ article | Ref:  ONO Pharmaceutical  | Image: Fate pharmaceutical